Harnessing the evolving CRISPR/Cas9 for precision oncology

Harnessing the evolving CRISPR/Cas9 for precision oncology

Abstract The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 system, a groundbreaking innovation in genetic engineering, has revolutionized our approach to surmounting complex diseases, culminating in CASGEVY™ approved for sickle cell anemia. Derived from a microbial immune de...

Full description

Bibliographic Details
Main Authors: Tianye Li, Shuiquan Li, Yue Kang, Jianwei Zhou, Ming Yi
Format: Article
Language:English
Published: BMC 2024-08-01
Series:Journal of Translational Medicine
Subjects:
CRISPR/Cas9
SpCas9
dCas9
Base editor
Chimeric antigen receptor
Precision oncology
Online Access:https://doi.org/10.1186/s12967-024-05570-4

Internet

https://doi.org/10.1186/s12967-024-05570-4

Similar Items